Journal Article10.1016/J.CANLET.2004.06.014
Cyclooxygenases in cancer: progress and perspective.
407
TL;DR: The rapid development of safe and effective inhibitors targeting individual COX enzymes not only dramatically improved the understanding of the function of COX-2, but also resulted in discovery ofCOX independent functions of NSAIDs, providing important hints for future drug design.
read more
About: This article is published in Cancer Letters. The article was published on 08 Nov 2004. The article focuses on the topics: Mouse model of colorectal and intestinal cancer & Cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
TL;DR: To assess cyclooxygenase‐2 (COX‐2) expression in sporadic colonic adenomas and to explore the association of COX-2 positivity with adenoma characteristics linked to increased risk of malignant transformation.
26
Efficacy of sulforaphane is mediated by p38 MAP kinase and caspase-7 activations in ER-positive and COX-2-expressed human breast cancer cells
Eun-Hye Jo,Sung-Hoon Kim,Nam-Shik Ahn,J. E. Park,Jae-Woong Hwang,Yong Soon Lee,Kyung-Sun Kang +6 more
TL;DR: The results suggest that sulforaphane may be an alternative candidate for targeted prevention of ER-positive and cyclooxygenase-2-induced phenotypes and breast cancer.
26
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro
TL;DR: The data obtained for the human prostate cancer cell lines do not indicate that a marked inhibition of prostaglandin E2 synthesis by celecoxib leads to enhanced radiosensitization, and the analysed prostate cancer cells can be classified as non-responders to cele Coxib treatment.
26
In Vitro and In Vivo Evaluation of the Anticancer and Anti-inflammatory Activities of 2-Himachelen-7-ol isolated from Cedrus Libani.
Andree Elias,Wassim N. Shebaby,Bilal Nehme,Wissam H. Faour,Bassem S. Bassil,Joelle El Hakim,Rita Iskandar,Nahia Dib-Jalbout,Mohamad Mroueh,Costantine F. Daher,Robin I. Taleb +10 more
TL;DR: It is demonstrated that 7-HC possesses promising anticancer and anti-inflammatory activities, and may serve as a lead molecule in cancer therapy.
Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer
TL;DR: Data suggest that TXA2 acts as both a neoplastic and epigenetic regulator and provides a mechanistic explanation, at least in part, for the prophylactic benefits of Aspirin in reducing the risk of certain cancers.
25
References
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
TL;DR: Experiments with guinea-pig lung suggest that some of the therapeutic effects of sodium salicylate and aspirin-like drugs are due to inhibition of the synthesis of prostaglandins.
8.8K
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
TL;DR: Important insights into the mechanisms of inflammatory responses, pain, and fever have been gleaned from the current understanding of eicosanoid biology.
3.8K
Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation
TL;DR: Leukotrienes C4, D4, and E4, which are released from the lung tissue of asthmatic subjects exposed to specific allergens, seem to play a pathophysiological role in immediate hypersensitivity reactions.
2.8K
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Charles E. Eberhart,Robert J. Coffey,Aramandla Radhika,Francis M. Giardiello,Suzanne Ferrenbach,Raymond N. DuBois +5 more
TL;DR: COX-2, but not COX-1, gene expression is markedly elevated in most human colorectal cancers compared with accompanying normal mucosa, and COx-2 expression seems to be increased in a subset of adenomas.
2.6K
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Gideon Steinbach,Patrick M. Lynch,R. K. S. Phillips,Marina Wallace,Ernest T. Hawk,Gary Gordon,Naoki Wakabayashi,Brian D. Saunders,Yu Shen,Takashi Fujimura,Li Kuo Su,Bernard Levin,Louis Godio,Sherri Patterson,Miguel A. Rodriguez-Bigas,Susan L. Jester,Karen L. King,Marta Schumacher,James L. Abbruzzese,Raymond N. DuBois,Walter N. Hittelman,Stuart O. Zimmerman,Jeffrey W. Sherman,Gary J. Kelloff +23 more
TL;DR: In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.
2.6K